Get Cash Back and $0 Commissions + The Power of TradeStation
CLASS ACTION UPDATE for TGTX, ACHC and ADNT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Globe Newswire 30-Nov-2018 1:43 PM
NEW YORK, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
The lawsuit alleges: TG Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) TG was involved in cleaning the data collected in the UNITY-CLL Trial; and as a result, was able to gain an understanding as to the efficacy of the combination therapy; (2) as a result of that data cleaning, TG knew the UNITY-CLL Trial had failed to meet its stated goal and as a result, the Company would not be able to seek accelerated approval; and (3) given that the UNITY-CLL Trial had failed to meet its stated goal, it was highly unlikely that the combination therapy would meet its primary endpoint of increased progression free survival.
The lawsuit alleges: Acadia Healthcare Company, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) the quality of Acadia's U.K. operations did not give the Company a "competitive strength" that would drive future growth and profitability; and (2) defendants had no reasonable basis to believe--and did not in fact believe--their positive statements about the Company's business and financial prospects during the Class Period, including their guidance issued and reaffirmed throughout the Class Period.
To learn more about the Acadia Healthcare Company, Inc. class action contact jlevi@levikorsinsky.com.
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements. In particular, the complaint alleges that defendants repeatedly stressed to investors that the Company was "solidly on track" to deliver 200-basis-point margin expansion by 2020, which was largely dependent on operational and financial improvements in Adient's core SS&M business, while unbeknownst to investors, Adient's core SS&M business faced significant operational problems such that the repeatedly touted 200-basis-point margin expansion was not "on track" at any point during the Class Period. Consequently, Adient stock traded at artificially inflated prices during the Class Period, reaching a high of $85.93 per share.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 55 Broadway, 10th Floor New York, NY 10006 jlevi@levikorsinsky.com Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
